Adult Burkitt lymphoma: advances in diagnosis and treatment. Oncology (Williston Park, N.Y.) [Oncology (Williston Park)] Journal article | | Title | Adult Burkitt lymphoma: advances in diagnosis and treatment. | | Author(s) | Aldoss IT, Weisenburger DD, Fu K, Chan WC, Vose JM, Bierman PJ, Bociek RG, Armitage JO | | Institution | Creighton University Medical Center, NE 68131-2197, USA. | | Source | Oncology (Williston Park) 2008 Nov 30; 22(13):1508-17; discussion 1518-9, 1522-3. | | Abstract | Burkitt lymphoma is a unique B-cell malignancy with a high proliferation rate and characteristic genetic changes involving the c-myc oncogene. Burkitt lymphoma is common in children but also occurs in adults, where distinction from diffuse large B-cell lymphoma may pose a problem. The development of brief, very intensive chemotherapy regimens has led to a very high cure rate in children with Burkitt lymphoma. The use of these regimens in adults, often in combination with the antibody rituximab (Rituxan), has also made the cure of a majority of adults possible. Burkitt lymphoma in adults cannot be treated effectively with the common regimens used for diffuse large B-cell lymphoma such as CHOP-R (cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], prednisone, rituximab). Prompt diagnosis and initiation of appropriate therapy with attention to the possibility of tumor lysis syndrome are necessary for optimal results. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19133605 |
|
|
| |
Advertise on this site.
| | |
|
